Leerink Partnrs Has Positive Estimate for REGN Q4 Earnings

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) - Equities researchers at Leerink Partnrs lifted their Q4 2024 EPS estimates for Regeneron Pharmaceuticals in a report released on Tuesday, January 28th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings of $9.82 per share for the quarter, up from their prior estimate of $8.81. The consensus estimate for Regeneron Pharmaceuticals' current full-year earnings is $37.73 per share. Leerink Partnrs also issued estimates for Regeneron Pharmaceuticals' Q1 2025 earnings at $6.80 EPS and FY2025 earnings at $33.55 EPS.

A number of other equities analysts have also commented on the stock. Bank of America reaffirmed an "underperform" rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Sanford C. Bernstein decreased their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a research report on Tuesday, January 7th. StockNews.com cut Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Monday, November 4th. Canaccord Genuity Group began coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They set a "hold" rating and a $165.00 price target on the stock. Finally, Truist Financial lowered their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating for the company in a research note on Wednesday, January 8th. One analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,004.57.

Regeneron Pharmaceuticals Trading Down 0.6 %

REGN traded down $4.27 on Thursday, reaching $683.00. 598,520 shares of the company traded hands, compared to its average volume of 873,151. The company has a market cap of $75.05 billion, a P/E ratio of 16.90, a price-to-earnings-growth ratio of 1.59 and a beta of 0.10. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a one year low of $666.25 and a one year high of $1,211.20. The firm has a fifty day simple moving average of $723.36 and a two-hundred day simple moving average of $928.61.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several hedge funds have recently modified their holdings of REGN. Creative Planning increased its position in shares of Regeneron Pharmaceuticals by 11.5% in the 2nd quarter. Creative Planning now owns 9,615 shares of the biopharmaceutical company's stock valued at $10,106,000 after acquiring an additional 991 shares during the period. NewEdge Advisors LLC increased its holdings in Regeneron Pharmaceuticals by 6.3% in the 2nd quarter. NewEdge Advisors LLC now owns 4,368 shares of the biopharmaceutical company's stock worth $4,591,000 after buying an additional 260 shares during the period. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Regeneron Pharmaceuticals by 16.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,821 shares of the biopharmaceutical company's stock worth $4,016,000 after buying an additional 536 shares during the last quarter. B. Riley Wealth Advisors Inc. boosted its holdings in Regeneron Pharmaceuticals by 8.0% during the second quarter. B. Riley Wealth Advisors Inc. now owns 1,086 shares of the biopharmaceutical company's stock worth $1,142,000 after buying an additional 80 shares in the last quarter. Finally, New Century Financial Group LLC acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth $313,000. Institutional investors and hedge funds own 83.31% of the company's stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.